Shots:
- Bio-Thera Solutions has commenced the patients dosing under the combined P-I/P-III study evaluating BAT3306, a biosimilar version of Keytruda (pembrolizumab)
- The trial aims at assessing PK profile, safety & efficacy of BAT3306 vs Keytruda among patients (n=676) with non-squamous non-small cell lung cancer (nsNSCLC)
- In addition, the company is also developing biosimilars of golimumab, secukinumab & mepolizumab plus includes BAT1806 (biosimilar of tocilizumab), approved by the US FDA, EMA & NMPA, BAT1706 (biosimilar of bevacizumab), approved by the US FDA & NMPA as well as BAT2206 (biosimilar of ustekinumab), filed with the US FDA, EMA & NMPA
Ref: Bio-Thera | Image: Bio-Thera | Press Release
Related News:- Bio-Thera Reports the Regulatory Filing Acceptance for BAT2206 (Biosimilar, Stelara) Across the US and EU
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
